Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: J Stone who wrote (26587)	11/17/1998 7:09:00 PM
From: celeryroot.com	Read Replies (1) \| Respond to of 32384

" . Management's collective behind is on the line right now in relation to the pending approval/postponement for Panretin Gel and for providing the FDA with the additional info needed for ONTAK" Please explain what you are talking about here. I think you may not understand the FDA process.

To: J Stone who wrote (26587)	11/17/1998 9:25:00 PM
From: jayhawk969	Read Replies (1) \| Respond to of 32384

R. Stone, Management's collective behind is on the line right now in relation to the pending approval/postponement for Panretin Gel and for providing the FDA with the additional info needed for ONTAK. According to Investor Relations(as of today), all information has been provided to the FDA by Ligand/Seragen and Ligand is awaiting FDA's reply on Ontak.

To: J Stone who wrote (26587)	11/18/1998 10:11:00 AM
From: Machaon	Respond to of 32384

<< We really don't want anymore hype from LGND about the pipeline. >> Yes we do. But we want significant developments and discoveries rather than hype. Reason: LGND's above average market value is based more on their pipeline and partnerships, rather than on Panretin Gel and Ontak. These two products represent initially small markets. OTOH, if I am not mistaken, Panretin Gel represents the FIRST topical treatment for a skin cancer. That, to me, is a big first step. Anyway, with 37 +/- products in the pipeline there is a high probability that we could see more frequent news going into the near future. I'd still like to hear something about their Phase II Diabetes II Targretin clinical tests, in progress since March 1997. That is a big market. Regards, Bob